Drug: Ivonescimab Injection + Drug: Bevacizumab Injection
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer (CRC)
Conditions
Metastatic Colorectal Cancer (CRC)
Trial Timeline
Nov 18, 2025 → Nov 30, 2029
NCT ID
NCT07228832About Drug: Ivonescimab Injection + Drug: Bevacizumab Injection
Drug: Ivonescimab Injection + Drug: Bevacizumab Injection is a phase 3 stage product being developed by Summit Therapeutics for Metastatic Colorectal Cancer (CRC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07228832. Target conditions include Metastatic Colorectal Cancer (CRC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07228832 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Colorectal Cancer (CRC)